These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 11113218)

  • 1. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study.
    Marler JR; Tilley BC; Lu M; Brott TG; Lyden PC; Grotta JC; Broderick JP; Levine SR; Frankel MP; Horowitz SH; Haley EC; Lewandowski CA; Kwiatkowski TP
    Neurology; 2000 Dec; 55(11):1649-55. PubMed ID: 11113218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
    Patel SC; Levine SR; Tilley BC; Grotta JC; Lu M; Frankel M; Haley EC; Brott TG; Broderick JP; Horowitz S; Lyden PD; Lewandowski CA; Marler JR; Welch KM;
    JAMA; 2001 Dec; 286(22):2830-8. PubMed ID: 11735758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.
    Rhoney DH; Coplin WM; Lin Y; Frankel M; Lyden PD; Levine SR
    J Stroke Cerebrovasc Dis; 2010 Jan; 19(1):40-8. PubMed ID: 20123226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.
    Hacke W; Donnan G; Fieschi C; Kaste M; von Kummer R; Broderick JP; Brott T; Frankel M; Grotta JC; Haley EC; Kwiatkowski T; Levine SR; Lewandowski C; Lu M; Lyden P; Marler JR; Patel S; Tilley BC; Albers G; Bluhmki E; Wilhelm M; Hamilton S; ; ;
    Lancet; 2004 Mar; 363(9411):768-74. PubMed ID: 15016487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
    Kwiatkowski T; Libman R; Tilley BC; Lewandowski C; Grotta JC; Lyden P; Levine SR; Brott T;
    Ann Emerg Med; 2005 Apr; 45(4):377-84. PubMed ID: 15795715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early neurologic improvement based on the National Institutes of Health Stroke Scale score predicts favorable outcome within 30 minutes after undergoing intravenous recombinant tissue plasminogen activator therapy.
    Takagi T; Kato T; Sakai H; Nishimura Y
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):69-74. PubMed ID: 23164483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial.
    Grotta JC; Welch KM; Fagan SC; Lu M; Frankel MR; Brott T; Levine SR; Lyden PD
    Stroke; 2001 Mar; 32(3):661-8. PubMed ID: 11239184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study.
    IMS Study Investigators
    Stroke; 2004 Apr; 35(4):904-11. PubMed ID: 15017018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
    Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
    National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
    Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraarterial thrombolytic therapy within 3 hours of the onset of stroke.
    Bourekas EC; Slivka AP; Shah R; Sunshine J; Suarez JI
    Neurosurgery; 2004 Jan; 54(1):39-44; discussion 44-6. PubMed ID: 14683539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Interventional Management of Stroke (IMS) II Study.
    IMS II Trial Investigators
    Stroke; 2007 Jul; 38(7):2127-35. PubMed ID: 17525387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NIHSS-time score easily predicts outcomes in rt-PA patients: the SAMURAI rt-PA registry.
    Aoki J; Kimura K; Koga M; Kario K; Nakagawara J; Furui E; Shiokawa Y; Hasegawa Y; Okuda S; Yamagami H; Okada Y; Shibazaki K; Sakamoto Y; Toyoda K
    J Neurol Sci; 2013 Apr; 327(1-2):6-11. PubMed ID: 23433814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
    Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
    Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated-measures analysis of the National Institute of Neurological Disorders and Stroke rt-PA stroke trial.
    Feng W; Vasquez G; Suri MF; Lakshminarayan K; Qureshi AI
    J Stroke Cerebrovasc Dis; 2011; 20(3):241-6. PubMed ID: 20621509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Very mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhage.
    Hassan AE; Hassanzadeh B; Tohidi V; Kirmani JF
    South Med J; 2010 May; 103(5):398-402. PubMed ID: 20375952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial.
    Bruno A; Levine SR; Frankel MR; Brott TG; Lin Y; Tilley BC; Lyden PD; Broderick JP; Kwiatkowski TG; Fineberg SE;
    Neurology; 2002 Sep; 59(5):669-74. PubMed ID: 12221155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial.
    Broderick JP; Lu M; Kothari R; Levine SR; Lyden PD; Haley EC; Brott TG; Grotta J; Tilley BC; Marler JR; Frankel M
    Stroke; 2000 Oct; 31(10):2335-41. PubMed ID: 11022060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
    Hertzberg V; Ingall T; O'Fallon W; Asplund K; Goldfrank L; Louis T; Christianson T
    Clin Trials; 2008; 5(4):308-15. PubMed ID: 18697845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.